Indira Brar is an Infectious Disease physician affiliated with Henry Ford Health. OpenAlex indexes 134 publications with 4,127 citations (h-index 23); ClinicalTrials.gov lists 1 registered study matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Publications indexed by OpenAlex, matched via ORCID. Counts exclude supporting files.
Citations across these publications.
H-index from these publications.
Clinical & industry
trials, payments and federal fundingClinical trials
- Post-Exposure Prophylaxis in Health Care Workers
Sponsor: Henry Ford Health System
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
9 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- Gilead Sciences, Inc.Program year202546 payments$41,300
- GileadProgram year20258 paymentsResearch$20,467
- ViiV Healthcare CompanyProgram year202526 payments$16,726
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward. Research funding is listed under each investigator the record names.
Medicare prescribing footprint (2023)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
79.6%Protease Inhibitor26%Prezista33%Symtuza26%Prezcobix20%Ritonavir19%Atazanavir Sulfate3%Part D<11 patientsHuman Immunodeficiency Virus Integrase Strand Transfer Inhibitor16.9%Tivicay58%Isentress12%Isentress Hd11%Dovato10%Juluca9%Part D<11 patients+ 10 more classes in this area
Cardiovascular
4.1%Statin2.7%Atorvastatin Calcium100%Part D≥13 patientsAldosterone antagonist (MRA)0.7%Spironolactone100%Part D<11 patients+ 1 more class in this area
Respiratory
3.8%Corticosteroid1.4%Flunisolide50%Fluticasone Propionate50%Part D<11 patientsOpioid Agonist1.4%Hydrocodone-Acetaminophen100%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Similar KOLs
Other experts from the same institution or the same specialty.
Philip Philip, MD
Henry Ford Health
David Lanfear, MD
Henry Ford Health
David Ozog, MD
Henry Ford Health
Jessica Mellinger, MD
Henry Ford Health
Thomas Walsh, MD
Cornell University
Douglas Richman, MD
University of California San Diego
Henry Masur, MD
National Institutes of Health
Vance Fowler, MD
Duke University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet. Reviewed account links and congress post links can appear separately. Absence of a section means “not yet looked,” never “none found.”